No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a highly selective, orally administered small molecule designed to inhibit AXL. James Bradley Lorens and David R. Micklem established the company on December 21, 2007, and it is based in Bergen, Norway.
www.oncoinvent.comNo one on the platform currently holds 0RU5.L.
No tracked institution reports a position in 0RU5.L as of their last filing.
No one on the platform has traded 0RU5.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 2616.6% | 107.4% | ||||
| Profit Margin % | -673.1% | -37703.9% | ||||
| Free Cash Flow Margin % | -549.1% | -38866.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $25M | +8.5% | $-40.69 | $-53.70–$-27.68 | — | 1 |
| 2027 | $20M | -20.0% | $-16.47 | $-21.73–$-11.21 | — | 1 |
| 2028 | $168M | +740.0% | $3.92 | $2.67–$5.17 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-19 | $-591.85 | $-0.21 | +100.0% |
| 2025-11-19 | $-5.81 | $-0.21 | +96.4% |
| 2025-02-26 | $-69.85 | $-69.85 | +0.0% |
| 2024-11-13 | $-85.87 | $-40.37 | +53.0% |
| 2024-08-21 | $-80.10 | $-89.08 | -11.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 0RU5.LOncoinvent ASA | $132.00 | -3.65% | $5.2B | — |
| 0M2Q.LYext, Inc. | $6.34 | -2.03% | $761M | — |
| AREC.LArecor Therapeutics plc | $85.26 | -0.28% | $32M | — |
| IUGNFImugene Limited | $0.04 | +0.00% | $20M | — |
Source: Financial Modeling Prep · peers by sector/industry